• 제목/요약/키워드: Targeted biopsy

검색결과 34건 처리시간 0.027초

MRI-Targeted Prostate Biopsy: What Radiologists Should Know

  • Chandan J Das;Arjunlokesh Netaji;Abdul Razik;Sadhna Verma
    • Korean Journal of Radiology
    • /
    • 제21권9호
    • /
    • pp.1087-1094
    • /
    • 2020
  • Transrectal ultrasound (TRUS)-guided systematic biopsy, the current gold standard for the detection of prostate cancer, suffers from low sensitivity for clinically significant cancer. The use of diagnostic multiparametric MRI has increased the relevance of targeted biopsy techniques such as MRI-TRUS fusion biopsy and direct (in-bore) MRI-guided biopsy, which have higher detection rate for clinically significant cancer. Although primarily used in patients who remain at high clinical suspicion for prostate cancer despite a negative systematic biopsy, with the increasing use of upfront diagnostic MRI, these biopsies are expected to replace routine systematic biopsies. This pictorial essay aims to enhance our understanding of the concepts of these biopsy techniques so that they can be performed safely and provide maximum diagnostic yield.

Paradigm Shift in Prostate Cancer Diagnosis: Pre-Biopsy Prostate Magnetic Resonance Imaging and Targeted Biopsy

  • Jung Jae Park;Chan Kyo Kim
    • Korean Journal of Radiology
    • /
    • 제23권6호
    • /
    • pp.625-637
    • /
    • 2022
  • With regard to the indolent clinical characteristics of prostate cancer (PCa), the more selective detection of clinically significant PCa (CSC) has been emphasized in its diagnosis and management. Magnetic resonance imaging (MRI) has advanced technically, and recent international cooperation has provided a standardized imaging and reporting system for prostate MRI. Accordingly, prostate MRI has recently been investigated and utilized as a triage tool before biopsy to guide tissue sampling to increase the detection rate of CSC beyond the staging tool for patients in whom PCa was already confirmed on conventional systematic biopsy. Radiologists must understand the current paradigm shift for better PCa diagnosis and management. This article reviewed the recent literature, demonstrating the diagnostic value of pre-biopsy prostate MRI with targeted biopsy and discussed unsolved issues regarding the paradigm shift in the diagnosis of PCa.

Initial experience of magnetic resonance imaging/ultrasonography fusion transperineal biopsy: Biopsy techniques and results for 75 patients

  • Tae, Jong Hyun;Shim, Ji Sung;Jin, Hyun Jung;Yoon, Sung Goo;No, Tae Il;Kim, Jae Yoon;Kang, Seok Ho;Cheon, Jun;Kang, Sung Gu
    • Investigative and Clinical Urology
    • /
    • 제59권6호
    • /
    • pp.363-370
    • /
    • 2018
  • Purpose: The aim of this study is to describe the technique and to report early results of transperineal magnetic resonance imaging and ultrasonography (MRI-US) fusion biopsy. Materials and Methods: A total of 75 patients underwent MRI-US fusion transperineal biopsy. Targeted biopsy via MRI-US fusion imaging was carried out for cancer-suspicious lesions with additional systematic biopsy. Detection rates for overall and clinically significant prostate cancer (csPCa) were evaluated and compared between systematic and targeted biopsy. In addition, further investigation into the detection rate according to prostate imaging reporting and data system (PI-RADS) score was done. Results of repeat biopsies were also evaluated. Results: Overall cancer detection rate was 61.3% (46 patients) and the detection rate for csPCa was 42.7% (32 patients). Overall detection rates for systematic and targeted biopsy were 41.3% and 57.3% (p<0.05), respectively. Detection rates for csPCa were 26.7% and 41.3%, respectively (p<0.05). The cancer detection rates via MRI fusion target biopsy were 30.8% in PI-RADS 3, 62.1% in PI-RADS 4 and 89.4% in PI-RADS 5. Rates of csPCa missed by targeted biopsy and systematic biopsy were 0.0% and 25.0%, respectively. The cancer detection rate in repeat biopsies was 61.1% (11 among 18 patients) in which 55.5% of cancer suspected lesions were located in the anterior portion. Conclusions: Transperineal MRI-US fusion biopsy is useful for improving overall cancer detection rate and especially detection of csPCa. Transperineal MRI-US targeted biopsy show potential benefits to improve cancer detection rate in patients with high PIRADS score, tumor located at the anterior portion and in repeat biopsies.

영상의학과 의사의 시각에서 본 자기공명영상 기반 전립선 표적 생검 (MR-Guided Targeted Prostate Biopsy from Radiologists' Perspective)

  • 김소연;박계진
    • 대한영상의학회지
    • /
    • 제84권6호
    • /
    • pp.1220-1232
    • /
    • 2023
  • 전립선암의 진단은 전립선을 10-12구역으로 나눠서 무작위로 조직을 얻는 체계적 생검 방식이 표준적으로 사용되어 왔다. 그러나 종괴의 위치나 유무와 상관없이 조직의 획득이 이루어지기 때문에 일부 전립선암을 놓치거나 임상적으로 중요하지 않은 암을 과도하게 발견한다는 점에서 비판을 받고 있다. 이를 보완하기 위해 자기공명영상 기반 전립선 표적 생검이 제안되었으며 이는 자기공명영상에서 의심 병변을 발견 후 이를 토대로 초음파 유도 혹은 MRI 유도하에 표적 생검을 하는 방식이다. 본 종설에서는 자기공명영상 기반 표적 생검의 방식에 대해서 살펴보고 최근 전립선암 진단에 있어서의 가이드라인과 최근 동향에 대해 다루고자 한다.

Circulating Tumor DNA in a Breast Cancer Patient's Plasma Represents Driver Alterations in the Tumor Tissue

  • Lee, Jieun;Cho, Sung-Min;Kim, Min Sung;Lee, Sug Hyung;Chung, Yeun-Jun;Jung, Seung-Hyun
    • Genomics & Informatics
    • /
    • 제15권1호
    • /
    • pp.48-50
    • /
    • 2017
  • Tumor tissues from biopsies or surgery are major sources for the next generation sequencing (NGS) study, but these procedures are invasive and have limitation to overcome intratumor heterogeneity. Recent studies have shown that driver alterations in tumor tissues can be detected by liquid biopsy which is a less invasive technique capable of both capturing the tumor heterogeneity and overcoming the difficulty in tissue sampling. However, it is still unclear whether the driver alterations in liquid biopsy can be detected by targeted NGS and how those related to the tissue biopsy. In this study, we performed whole-exome sequencing for a breast cancer tissue and identified PTEN p.H259fs*7 frameshift mutation. In the plasma DNA (liquid biopsy) analysis by targeted NGS, the same variant initially identified in the tumor tissue was also detected with low variant allele frequency. This mutation was subsequently validated by digital polymerase chain reaction in liquid biopsy. Our result confirm that driver alterations identified in the tumor tissue were detected in liquid biopsy by targeted NGS as well, and suggest that a higher depth of sequencing coverage is needed for detection of genomic alterations in a liquid biopsy.

Effect of Route of Preoperative Biopsy on Endoscopic Submucosal Dissection for Patients with Early Gastric Cancer

  • Jiang, Hui;Tu, Hui-Ming;Qiao, Qiao;Xu, Ke-Bin;Li, Jie;Qi, Xiao-Wei;Ge, Xiao-Song
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제15권20호
    • /
    • pp.8917-8921
    • /
    • 2014
  • Objective: To observe and compare the effects of multi-patch biopsy under conventional white light imaging endoscopy (C-WLI) and precise targeted biopsy under magnifying narrow-band imaging endoscopy (M-NBI) on the endoscopic submucosal dissection (ESD) of early gastric cancers and intraepithelial neoplasias. Methods: According to the way of selecting biopsy specimens, patients were divided into C-WLI and M-NBI groups, 20 cases. The ESD operations of the 2 groups were compared quantitively. Results: The mean frequency of biopsy in M-NBI group was ($1.00{\pm}0.00$), obviously lower than in the C-WLI group ($4.78{\pm}1.02$) (P<0.01).The average total number of selected biopsy specimens was also fewer ($1.45{\pm}0.12$ and $7.82{\pm}2.22$, respectively, P<0.01). There was no significant difference in the time of determining excision extension, marking time and the time of specimen excision of 2 groups during the ESD (P>0.05), whereas submucosal injection time, mucosal dissection time, stopping bleeding time, wound processing time in the M-NBI group were significantly shorter than in the C-WLI group (P<0.01). Conclusion: Precise targeted biopsy under M-NBI can obviously shorten the time of ESD operation, with small quantity of tissues but high pathological positive rate.

New Targeted Therapy for Non-Small Cell Lung Cancer

  • Eun Ki Chung;Seung Hyun Yong;Eun Hye Lee;Eun Young Kim;Yoon Soo Chang;Sang Hoon Lee
    • Tuberculosis and Respiratory Diseases
    • /
    • 제86권1호
    • /
    • pp.1-13
    • /
    • 2023
  • Lung cancer ranks first in cancer mortality in Korea and cancer incidence in Korean men. More than half of Korean lung cancer patients undergo chemotherapy, including adjuvant therapy. Cytotoxic agents, targeted therapy, and immune checkpoint inhibitors are used in chemotherapy according to the biopsy and genetic test results. Among chemotherapy, the one that has developed rapidly is targeted therapy. The National Comprehensive Cancer Network (NCCN) guidelines have been updated recently for targeted therapy of multiple gene mutations, and targeted therapy is used not only for chemotherapy but also for adjuvant therapy. While previously targeted therapies have been developed for common genetic mutations, recently targeted therapies have been developed to overcome uncommon mutations or drug resistance that have occurred since previous targeted therapy. Therefore, this study describes recent, rapidly developing targeted therapies.

신장의 조직 검사 (Renal Biopsy)

  • 김택민;조정연;김상윤
    • 대한영상의학회지
    • /
    • 제84권6호
    • /
    • pp.1198-1210
    • /
    • 2023
  • 최근에 우연히 발견되는 신장 종괴의 증가와 국소 치료, 표적 치료와 같은 신장암 치료 선택지의 다양화, 그리고 신장 이식의 보편화에 따라서 신장의 조직 검사가 증가하고 있는 추세이다. 그러나 신장은 피부부터 장기까지의 거리가 멀어 조직 검사의 난이도가 높은 편으로 특히 초심자들은 신장의 조직 검사를 부담스럽게 여길 수 있다. 이 종설에서 우리는 신장 조직 검사의 적응증과 기술적인 고려 사항들, 진단 정확도, 그리고 합병증에 대해서 알아보겠다. 특히 실전적인 팁들을 다양한 증례들과 함께 알아보며 다양한 상황에서도 안전하고 효과적으로 조직 검사를 시행할 수 있게 도움이 되고자 한다.

전립선 생검: 일반적 고려사항 및 체계적 생검 (Prostate Biopsy: General Consideration and Systematic Biopsy)

  • 안형우
    • 대한영상의학회지
    • /
    • 제84권6호
    • /
    • pp.1211-1219
    • /
    • 2023
  • 한국은 급속하게 고령화 사회로 진입하고 있으며, 이로 인한 전립선암과 관련된 사회경제적 부담 증가는 불가피하다. 따라서, 전립선암의 조기 발견과 정확한 진단의 필요성은 더욱 높아지고 있다. 일반적으로 이상적인 생검은 최소 숫자의 생검 코어만으로 암을 정확히 찾아낼 수 있어야 한다. 그러나 전립선암은 영상에서 뚜렷한 이상 소견으로 드러나지 않을 수 있기 때문에, 이미지 유도 표적 생검만으로 진단에 충분하지 않다. 따라서 수십 년의 시행착오와 변천을 거쳐, 전립선암 진단은 실질 전반에 대한 무작위적이고 반복적인, 이른바 체계적 생검에 의존하고 있다. 이 종설을 통해 전립선암 진단법의 변천사를 살펴보고, 전립선 생검에 있어 일반적으로 고려해야 할 사항들과 생검 전후의 환자 관리에 대해서 다루고자 한다.

Transventricular Biopsy of Brain Tumor without Hydrocephalus Using Neuroendoscopy with Navigation

  • Song, Ji-Hye;Kong, Doo-Sik;Seol, Ho-Jun;Shin, Hyung-Jin
    • Journal of Korean Neurosurgical Society
    • /
    • 제47권6호
    • /
    • pp.415-419
    • /
    • 2010
  • Objective : It is usually difficult to perform the neuroendoscopic procedure in patients without hydrocephalus due to difficulties with ventricular cannulation. The purpose of this study was to find out the value of navigation guided neuroendoscopic biopsy in patients with peri- or intraventricular tumors without hydrocephalus. Methods : Six patients with brain tumors without hydrocephalus underwent navigation-guided neuroendoscopic biopsy. The procedure was indicated for verification of the histological diagnosis of the neoplasm, which was planned to be treated by chemotherapy and/or radiotherapy as the first line treatment, or establishment of the pathological diagnosis for further choice of the most appropriate treatment strategy. Results : Under the guidance of navigation, targeted lesion was successfully approached in all patients. Navigational tracking was especially helpful in entering small ventricles and in approaching the third ventricle through narrow foramen Monro. The histopathologic diagnosis was established in all of 6 patients : 2 germinomas, 2 astrocytomas, 1 dysembryoplastic neuroepithelial tumor and 1 pineocytoma. The tumor biopsy sites were pineal gland (n = 2), suprasellar area (n = 2), subcallosal area (n = 1) and thalamus (n = 1). There were no operative complications related to the endoscopic procedure. Conclusion : Endoscopic biopsy or resection of peri- or intraventricular tumors in patients without hydrocephalus is feasible. Image-guided neuroendoscopic procedure improved the accuracy of the endoscopic approach and minimized brain trauma. The absence of ventriculomegaly in patients with brain tumor may not be served as a contraindication to endoscopic tumor biopsy.